Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
20 hedge funds and large institutions have $1.56M invested in Statera Biopharma, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.
425% more capital invested
Capital invested by funds: $298K → $1.56M (+$1.27M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 18 → 20 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$515K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$287K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$125K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$51.4K |
| 5 |
BlackRock
New York
|
+$37.1K |
Top Sellers
STAB Hedge Fund Activity: Q2 2017 in Review
20 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2017, worth a combined $1.56M — up 425% from $298K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new STAB positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $515K.
- 20 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2017, up from 18 in Q1 2017.
- Funds reported $1.56M of Statera Biopharma, Inc. Common Stock stock for Q2 2017, up 425% quarter-over-quarter.
- 4 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2017 was Renaissance Technologies, an estimated $515K added.
Based on aggregated 13F filings for Q2 2017.